Elsevier

Leukemia Research

Volume 34, Issue 7, July 2010, Pages e176-e177
Leukemia Research

Letter to the Editor
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCRABL chronic myeloid leukemia

https://doi.org/10.1016/j.leukres.2010.01.025Get rights and content

Introduction

Approximately 90–95% of chronic myeloid leukemia (CML) patients have evidence of a Philadelphia (Ph) chromosome with nearly all expressing either one or both e13a2 or e14a2 BCRABL fusion transcripts [1]. A number of variant transcripts arising from outside the usual breakpoint regions of both BCR and ABL genes have been described in CML that involve either fusion of alternate exons, insertions or breakpoints within exons. Rarely, e1a2 BCRABL transcripts, usually associated with Ph-positive acute lymphoblastic leukemia, are found to be the sole BCRABL species in CML. Although the introduction of imatinib therapy has been a major advance in the treatment of CML [2], response to imatinib in e1a2 BCRABL CML has until recently been anecdotal [3], [4]. Two recent reports identifying patients with e1a2 BCRABL CML have highlighted the relatively poor response to frontline imatinib and subsequent tyrosine kinase inhibitor (TKI) therapy in this genotype [5], [6]. Complete cytogenetic and molecular responses are infrequent and when obtained, are often short-lived, suggesting close molecular monitoring throughout treatment with allogeneic stem cell transplantation, if eligible, to be considered early in this disease. Mutations in the ABL kinase domain may not completely explain the poor outcome with resistance possibly mediated by BCR-ABL independent mechanisms [6]. A patient with e1a2 BCRABL CML is described who achieved a hematological remission, a delayed complete cytogenetic remission (CCyR) and who maintains only a suboptimal molecular response to imatinib therapy though remaining clinically stable for longer than 2 years after initial presentation.

Section snippets

Case report

A 61-year-old female presented with an incidental finding of a raised white blood cell count. She suffered from a non-q wave myocardial infarction 7 years previously and was otherwise well. Peripheral full blood count showed WCC 35.4 × 109/L with a monocytosis of 3.89 × 109/L, hemoglobin of 17.4 g/L, platelets 627 × 109/L and a basophilia of 0.35 × 109/L. Atypical monocyte morphology was noted with no peripheral blasts and there was no palpable spleen. The patient had a low risk Sokal score of 0.78. The

Discussion

Variant BCRABL fusion genes afford the opportunity to explore genotype–phenotype relationships in CML with the monocytosis and atypical monocyte morphology observed at diagnosis in this patient characteristic of e1a2 BCRABL CML [8]. However, it remains unclear whether relatively small numbers of patients with these variant transcripts have similar responses and prognoses to e13a2/e14a2 BCRABL CML. Although infrequent case reports have described a relatively indolent clinical course even

Conflict of interest

The authors report no conflicts of interest.

Acknowledgements

None.

Contributions. S.E.L. conceived the study and wrote the letter. M.C. and K.H. performed RQ-PCR analysis. J.K. performed cytogenetic analysis. M.R.C. provided patient care and clinical information.

Cited by (0)

View full text